City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a ...

Although real progress has been made in managing depression over recent decades, significant hurdles remain. In fact, around ...

The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight ...

"Treating thyroid eye disease requires balancing efficacy, safety, and the practical realities of long-term treatment," said ...

The CHMP has backed Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least ...

The list of illnesses that seem to benefit from treatment with GLP-1 agonists seems to get ever longer, and a study has ...

Reimbursement authority NICE has turned down routine NHS use of Roche's Itovebi for a specific form of breast cancer, a ...

August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...

Fragmented data does more than slow trials down. In some cases, it can limit eligible patients from participating in a trial ...

Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with mid-stage clinical data for a new shot covering 25 strains – five more than its current Prevnar 20 ...

Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin mimetic, ...

GSK is preparing to cut more than 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched ...